Companies debut federal distribution collaboration to VA leadership, administrators and physicians at NAVREF 2026 bioAffinity engages GO2 for Lung Cancer…
bioAffinity Technologies, Inc. (BIAF) filed an SEC Form 8-K — Other Events. Exhibit 99.1 News Release bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL Companies debut federal distribution collaboration to VA leadership, administrators a
How this was made
The 30-second read
Why it matters
The deal expands access to VA facilities, potentially increasing sales volume, but the financial terms are undisclosed, limiting immediate price impact.
Market read
A new federal distribution channel for a biotech diagnostic could be a catalyst for BIAF, though the scale is uncertain.
What to watch
Potential delays in government procurement approvals and competition from other lung‑cancer screening technologies.
Background
bioAffinity Technologies (Nasdaq: BIAF) develops a non‑invasive lung cancer test (CyPath® Lung) and announced a distribution partnership with AvMEDICAL, a veteran‑owned federal supplier, at the NAVREF 2026 conference.
Ticker impact
bioAffinity Technologies disclosed a new federal distribution agreement with AvMEDICAL to sell its CyPath® Lung cancer test to VA facilities.
potential modest upside as investors price in expanded government channel
Distribution agreements with a veteran-owned federal supplier may boost revenue, but the deal size is not disclosed and the company remains a micro‑cap.
Market effects
Highlights growing focus on veteran healthcare and non‑invasive lung cancer diagnostics within the biotech sector.
May raise awareness of biotech opportunities among U.S. federal healthcare contractors.
Limited to U.S. federal market; no immediate global impact.
Counterpoint
The partnership's revenue upside may be overstated given the small scale and regulatory hurdles for LDTs.
Key entities
- companybioAffinity Technologies, Inc.
Developer of the CyPath® Lung non‑invasive cancer test.
- companyAvMEDICAL
Service‑Disabled Veteran‑Owned Small Business acting as federal distribution partner.
